Program
VSA003
A development code.
Its studies are mostly in Homozygous Familial Hypercholesterolemia · Dyslipidemias, led by Visirna Therapeutics HK.
Furthest: phase 3, since Nov 26, 20242 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Visirna Therapeutics HK | 21 open or running | phase 3since Nov 26, 2024 | Apr 26, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 26, 2023First study: phase 1 study in DyslipidemiasFirst studyNCT05851066 · 36 enrolled · China
- Nov 26, 2024Phase 3 study in Homozygous Familial HypercholesterolemiaNCT06712771 · 46 enrolled · China
TargetBeta
ANGPTL3 →read by rule
“In this clinical study, the efficacy and safety of VSA003, an RNAi-based therapeutic targeting ANGPTL3, will be evaluated in subjects with HoFH.”study text, by rule · the study
Other programs on ANGPTL3
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06712771Homozygous Familial Hypercholesterolemia · China | 3 | Active, not recruiting | Dec 31, 2025 | 46 |
| NCT05851066Dyslipidemias · China | 1 | Completed | May 7, 2024 | 36 |
How it is read
Names in the registry
- “VSA003”, 2 entries
Codes read as this program: VSA003.
Conditions, from the studies’ own filings
- Homozygous Familial Hypercholesterolemia, 1 study
- Dyslipidemias, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.